MedTrace Logo

Diabetic Nephropathy, Glycemic Control and Pseudophakic Macular Edema After Cataract Surgery

NCT07723846 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 428

Last updated 2026-07-24

No results posted yet for this study

Summary

This retrospective cohort study examines whether the kidney complications of diabetes (diabetic nephropathy) and blood-sugar control before surgery help predict swelling of the central retina, called pseudophakic macular edema (PME), after cataract surgery in people with type 2 diabetes.

PME is a common cause of blurred vision after otherwise successful cataract surgery, and people with diabetes are at higher risk. Doctors currently estimate this risk mainly from the HbA1c blood-sugar level and the stage of diabetic eye disease (retinopathy). It is not yet known whether diabetic kidney disease, measured by the urine albumin-to-creatinine ratio (UACR) and estimated kidney function (eGFR), adds independent information about who will develop PME.

Using medical records already collected during routine care at Thammasat University Hospital, the investigators will measure central retinal thickness on optical coherence tomography (OCT) scans before uncomplicated phacoemulsification cataract surgery with a lens implant, and again 1 and 3 months afterward. PME is defined as at least a 30% increase in central macular thickness. Patients with and without baseline diabetic nephropathy will be compared, and statistical modeling will identify the best preoperative HbA1c threshold for predicting PME.

The results are intended to improve preoperative risk counseling and to help identify diabetic patients who may need closer monitoring after cataract surgery. Because only existing records are used, the study involves no additional visits, tests, or risks for patients.

Conditions

  • Pseudophakic Macular Edema
  • Diabetic Nephropathies
  • Diabetes Mellitus, Type 2
  • Cataract (Post-operative Cataract Surgery Follow-up)
  • Cataract and IOL Surgery

Interventions

OTHER

Phacoemulsification with posterior-chamber IOL

Uncomplicated phacoemulsification cataract surgery with posterior-chamber intraocular lens implantation. The observed exposure of interest is baseline diabetic nephropathy and preoperative glycemic status (used to define the two cohorts).

Sponsors & Collaborators

  • Thammasat University

    collaborator OTHER

  • Thammasat University Hospital

    collaborator OTHER

  • Thammasart University Hospital

    lead OTHER

Principal Investigators

  • Nattapon Wongcumchang, Associate Professor · Vitreoretinal unit, Department of Ophthalmology, Faculty of medicine, Thammasat University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2026-11-01
Completion
2026-11-01

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07723846 on ClinicalTrials.gov